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Letters to the Editor
Comparison of assays used for in vitro chemosensitivity
testing of human tumours
Sir - In a recent issue of the journal, Dr A.P.
Wilson and her colleagues (Wilson et al., 1984)
purported to compare the applicability of
biochemical, monolayer and clonogenic assays for
the testing of human tumours. It is our opinion
that these authors beg the question that they had
hoped to prove as they did not work with
appropriate starting materials. It is indeed quite
clear that when one established tumour cell lines, it
is possible to develop assay conditions for
chemosensitivity testing in which quite similar
results can be obtained with a variety of assay
techniques. While the authors have cautioned that
their conclusion applies for tumours with a pure
population of tumour cells (a situation which rarely
exists in spontaneous human tumours), they should
have included the proviso that this comparison
would be valid only for purified clonogenic
populations of human tumours (which clearly are
unavailable). The only purified populations of
clonogenic human tumour cells which are currently
available are those which can be derived by
comparison of continuous cell lines. While tumour
cell lines are not 100% clonogenic, they commonly
have plating efficiencies of 50% or greater. Thus,
the comparison which the authors have made is of
several highly clonogenic tumour cell lines with a
variety of cytotoxic drugs. Their conclusions,
therefore, apply only to cell lines and, in our
opinion, cannot be extrapolated to fresh human
tumours. The major test for any chemosensitivity
assay is a prospective and not a retrospective
correlation. The authors also state that several
groups have failed to repeat the original findings
with clonogenic assays, however, they have chosen
to select the two negative studies rather than the
number of positive studies using such methods. We
recently reviewed (Salmon, 1984) the human
tumour clonogenic assay which clearly substantiates
the predictive capacity of this assay system. Perhaps
most important was the large prospective trial of
Von Hoff et al. The overall use of any
chemosensitivity assay for clinical purposes,
however, requires validation by randomized trial to
clinician-selected versus assay-selected agents. This
has yet to be reported for any major assay
methodology or tumour type.
Wilson et al. should be encouraged to carry out
comparative studies of biochemical, morphologic
and short-term biochemical assay systems on fresh
human tumours to determine whether the same
results will be obtained in that setting. The
confounding variables which can influence the
results of assays which do not use semisolid
medium and the clonogenic methodology include
the growth of non-neoplastic stromal cells, and the
potential difference in drug effect on clonogenic
versus non-clonogenic tumour cells. Direct
comparisons of such methodology on spontaneous
human tumours is the needed approach to provide
an accurate comparison of different assays. We do
not concur in their conclusions that their results on
cell lines as well as the fact that retrospective
correlations have been obtained with different assay
techniques make the matter of assay techniques
irrelevant.
Yours etc.,
S.E. Salmon, F.L. Meyskens & D.S. Alberts
Arizona Cancer Center
University of Arizona College of Medicine
Tucson, Arizona 85724, USA
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